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    INTRODUCTION 
 
 
 
 
 Despite effects at vector control, malaria still remains a major public 
health problem. Malaria remains to be one of the world’s most prevalent 
infectious diseases. About 300 – 500 million cases are reported annually 
allover the world with a mortality of about 1.1 to 2.7 million. 90% of these 
cases are reported from Africa. In India, 2.5 to 3 million cases and 1000 deaths 
of malaria are reported annually. Many consider this is an underestimate. The 
parasite profile has been changing significantly over the years with a steady 
increase in percentage of PF cases across the country (50.5% of cases in 2005). 
Areas with more than 30% of PF cases are categorized as high risk. These 
include North East India, Orissa, Jharkand, West Bengal, Madhya Pradesh, 
Maharashtra & Andrapradesh. In Tamil Nadu 70% of malaria cases are 
reported from Chennai.  Malaria is highly prevalent in places from North 
Chennai like Tondaiarpet, Washermanpet, Royapuram, Harbour, Mannady, 
Pattalam & Pulianthope. This study was undertaken at Stanley Medical college 
Hospital which is located in North Chennai. This study deals with clinical and 
laboratory profile of Malaria in North Chennai. 
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AIM 
 
 
To study the clinical  profile of Plasmodium Vivax and Plasmodium 
Falciparum malaria in north Chennai 
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REVIEW            
OF    
LITERATURE 
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   REVIEW OF LITERATURE 
 
EPIDEMIOLOGY 
 Malaria is the most important parasitic infection of human beings which 
still produces considerable morbidity and mortality world wide especially in 
tropical countries. There are four species of genus plasmodium that infects 
humans. They are plasmodium vivax, plasmodium palciparum, plasmodium 
ovale and plasmodium malariae. Though most of the complications and deaths 
were caused by plasmodium falciparum , plasmodium vivax is also reported to 
produce complications in the recent past. The dream of eradicating malaria got 
a set back due to widespread resistance of vectors to various insecticides and 
the resistance developed by malarial parasites for various drugs. The 
understanding of immunology against malaria has thrown light into host factors 
playing major role in pathogenesis of various complications. Development of 
vaccines is complicated by presence of multiple stages of parasite and high 
antigenic variation by the plasmodium. In this study various clinical features 
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and complications of plasmodium vivax and falciparum were analyzed in 
detail.     
 About 300 – 500 million cases are reported annually allover the world 
with a mortality of about 1.1 to 2.7 million.1 90% of these cases are reported 
from Africa. In India, 2.5 to 3 million cases and 1000 deaths of malaria are 
reported annually.2 Many consider this is an underestimate. Malaria is 
prevalent through out the tropics. Plasmodium falciparum predominates in 
Africa where as plasmodium vivax is more common in India . Plasmodium 
ovale and malariae were reported mainly from Africa. Malaria is transmitted by 
Female Anapheline Mosquito. Transmission does not occur in temperature < 
16 C or > 33 C and above 2000m Altitudes. In India the main vector is 
Anapheline stephensi which breeds in wells and stagnant water. 
 The endemicity of Malaria is defined in terms of spleen rate or parasite 
rate in children aged 2-9 yrs as follows: 
     Spleen/ parasite rate 
 Hypo endemic - 0 – 10 % 
 Meso endemic  - 10% - 50% 
 Hyper endemic - 50% - 75% 
 Holo endemic - > 75% 
  
 Severe malaria is uncommon in infants because of maternal antibodies 
and the presence of Hb F which offers innate resistance against malaria. In 
holoendemic areas, severe anemia and cerebral malaria occurs mainly in 
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children < 5 yrs of age and seldom occurs in adults as they develop a state of 
premunition. Where as in hypoendemic areas and areas with unstable 
transmission, where the immunity is partial , complicated malaria is common 
among the adults in the form of  jaundice, renal failure and multiple organ 
failure (MODS).3 In pregnant women MODS is common than cerebral malaria. 
Malaria can also be transmitted by blood transfusion, needle sharing and 
transplantation. 
 
RELATIVE INCIDENCE OF COMPLICATIONS 
  ADULTS PREGNANT CHILDREN 
ANEMIA + ++ +++ 
CONVULSIONS + + +++ 
HYPOGLYCEMIA + +++ +++ 
JAUNDICE  +++ +++ + 
RENAL FAILURE +++ +++ - 
PUL EDEMA ++ +++ + 
 
LIFE CYCLE OF MALARIAL PARASITE 
 Malarial parasite has two stages of development, sexual and asexual 
cycle. Mosquito is the definitive host and humans are intermediate host, so 
sexual cycle (sporogony)  occurs in mosquito and asexual cycle (schizogony) in 
humans. The time taken for the development of  malarial parasite in the 
mosquito is called as extrinsic incubation period. Once the sporozoite enters the 
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human after the mosquito bite, they reach the liver and hepatic schizogony 
leads on to release of merozoites, which in turn infects the RBCs. Some 
merozoites in case of  
 
 
SEXUAL CYCLE IN MOSQUITO 
MALE & FEMALE
GAMETOCYTE
IN HUMAN
BLOOD MEAL GUT OF 
MOSQITO
MALE & FEMALE
MICROGAMETE
FERTILISATION
ZYGOTE
OOKINETE
OOCYSTMIGRATES TO SALIVARY GLAND
SPOROGONY
SPOROZOITES
COELOMIC CAVITY
HUMAN
 
ASEXUAL CYCLE IN HUMAN BEING 
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BITE
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SCHIZOGONY
BLOOD VESSEL
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HEPATOCYTES
HYPNOZOITES
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RBC
ERYTHROCYTIC 
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REINFECTS
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CLINICAL 
PAROXYSM
MALE & FEMALE
GAMATOCYTE
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plasmodium vivax and ovale pass in to a stage of exo erythrocytic cycle within 
the liver which might cause relapse. Erythrocytic schizogony occurs cyclically  
once in 48 hrs ( PV,PO & PF) and 72 hrs in case of plasmodium malariae. The 
release of merozoites from RBCs co inside with the clinical paroxysm. Thus 
PV,PF & PO produces fever once in 2 days (tertian malaria) and PM once in 3 
days ( quartan malaria).  
 
INCUBATION PERIOD: 
PLASMODIUM VIVAX  - 12 days 
PLASMODIUM FALCIPARUM - 09 days 
PLASMODIUM OVALE  - 15 days 
PLASMODIUM MALARIAE - 18 days 
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NATURAL PROTECTION AGAINST MALARIA 
 The following defects in hemoglobin and HLA B 53 protects against 
malarial disease: 
1. Sickle cell trait 
2. Melanesian ovulocytosis 
3. G6PD deficiency 
4. Thalassemia  
5. Hemoglobin F 
6. HLA B 53 
IMMUNOLOGY 
 Immunity against malaria is highly complex. Non specific immunities 
against malaria are activation of phagocytes (Neutrophils & Macrophages) and 
augmentation of splenic clearance (filtration & antibody mediated 
phagocytosis). Infected RBCs are more rigid and opsonised more easily than 
uninfected RBCs. 
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IMMUNOLOGY
B CELL T CELL
CD4 CD8
POLYCLONAL  ACTIVATION
FALSE +VE SEROLOGICAL TESTS
NON SPECIFIC
NON PROTECTIVE
MACROPHAGEHUMORAL CMI
KILLS INFECTED RBCS
RBC LACKS HLA I AG
POLYCLONAL  AB BLOCKS CMI
COMPLEX INTERACTION
PREMUNITION
INFECTIONS HIGH ANTIGENIC VARIATION
NO LASTING  IMMUNITY
NO VACCINE
 
Humoral immune response in malaria is a type of polyclonal B cell activation 
where there is production of various types of non specific antibodies to various 
plasmodium antigens. There is a temporary phase of immune suppression that      
B cells are defective in raising a specific immune response against bacterial 
infection. So patients with malaria are temporarily prone for bacterial infections 
like UTI, pneumonia & salmonellosis. More over this polyclonal antibodies 
block the surface antigens of parasite there by impeding the cell mediated 
immunity to effectively eliminate the parasite. 
 Cell mediated immunity plays a major role in controlling the malarial 
infection as the parasite is a intracellular organism. CD8 cells are the important 
effector cells in killing the parasite infected RBCs. As the RBCs lack HLA 
class I antigen and since the parasite undergoes high antigenic variation CD8 
cells can not effectively protect against Malaria.  
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 There is a complex interaction between humoral and cell mediated 
immunity which leads on to a state of premunition where in the immunity 
against malarial disease persists as long as the host is staying in endemic area 
and constantly exposed to asymptomatic infection. Once the host moves out of 
endemic area for a prolonged period, host once again becomes vulnerable for 
malarial disease. It is interesting to note that AIDS does not worsen malaria. 
Hence our understanding of immunity against malaria is still unclear. 
 
PATHOPHYSIOLOGY 
 The pathophysiology of malaria results from destruction of RBC, 
liberation of parasite and erythrocyte material which elicits host reaction. 
 
 
 
 
 
CYTOKINES 
 A glycolipid material, similar to bacterial endotoxin released during 
meront rupture activate monocyte- macrophage and endothelium which in turn 
leads on to synthesis and release of TNF alpha,4 IL – 1, IL – 6 and IL – 8. 
These cytokines are responsible for symptoms and signs of malaria especially 
fever, malaise, headache and chills. They inhibit gluconeogenesis there by 
contributing to hypoglycemia. In CNS they stimulate the production of nitric 
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oxide by cerebral endothelium which inhibits neurotransmisin and leads to 
coma.  
 
PARASITE 
MACROPHAGE
ACTIVATION
CYTOKINE
TNF alpha
IL 6
VASODILATATION
PERMEABILITY
FEVER
SEPSIS SYNDROME
CHOLESTASIS
MULTIPLE ORGAN 
FAILURE
ADHESION MOLECULE
 
 
 Cytokines upregulates the endothelial adhesion molecules there by 
favouring cytoadherence. In high concentrations they produce cholestasis, 
peripheral vasodilatation and shock leading on to Multiple Organ 
Dysfunction(MODS). They also activates parasite killing by the leucocytes. 
Thus at appropriate concentration cytokines are protective and when released in 
high concentrations, they lead on to complications. Thus host factors also play 
a role in development of complication. 
 
ROSETTING 
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 Erythrocytes containing mature parasite also adhere to uninfected 
erythrocytes to form Rosettes. Infected RBCs express adhesion molecules               
in the form of knobs ( Hystidine Rich Protein HRP in case of Falciparum )5 
which is capable of binding with CD36 receptors on infected and uninfected 
RBCs  and platelets (CD36 & TSP transpondin) resulting in formation of 
Rosette. These Rosettes are capable of blocking microcirculation which leads 
on to stasis, anaerobic glycolysis there by reducing the PH at capillaries which 
in turn facilitates cytoadherence. Rosetting is encountered in vivax, falciparum 
and ovale malaria. 
 
CYTOADHERENCE 
 Cytoadherence is the attachment of infected erythrocytes to vascular 
endothelium. This phenomenon is exhibited by plasmodium falciparum which 
expresses PfEMP ( Erythrocyte membrane protein) on RBC surface that binds 
to venular endotheliam through the adhesion molecules CD36, Intercellular  
Adhesion Molecule -1( ICAM-1),6 Thrombospondin(TSP), Vascular 
Endothelial Adhesion Molecule (VCAM) and Endothelial Leucocyte Adhesion 
Molecule -1(ELAM-1). By cytoadherence, infected RBCs are trapped within 
the capillaries and venules of various internal organs there by avoiding splenic 
elimination. 
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PATHOGENESIS
PV / PF
INFECTED
RBC
MATURED PARSITE
WITH ADHESION
MOLECULES
UNINFECTED RBCS
ROSSETING
BOTH PV/PF
CYTOADHERENCE/SEQUESTRATION
ONLY BY PFVENULE/CAPILLARY
MICRO CIRCULATION
BRAIN
KIDNEY
LIVER STASIS,   PH, TNF/IL 6
 
Together Rosetting and Cytoadherence leads on to microcirculatory block and 
multiple organ dysfunction. In splenectomised animals PF infected RBCs does 
not exhibit cytoadherence, so spleen might have a modulating role for 
cytoadherence. 
 
 
ADHESION MOLECULES ON VASCULAR ENDOTHELIUM 
 As seen above there are number of endothelial adhesion molecule which 
binds PfERP. They are CD36, ICAM-1,6 VCAM & ELAM-1. ICAM-1 appears 
to be the major vascular ligand in the brain involved in cerebral sequestration 
and CD36 is the major ligand in other organs. Thus Plasmodium Falciparum 
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strains with high affinity to   ICAM-1  produces cerebral malaria where as 
strains with affinity to CD36 leads on to MODS. 
ADHESION MOLECULES
CD 36
UNINFECTED RBC INFECTED RBC
KNOBS – PfEMP1
PV+
EXTRACRANIAL ENDOTHELIUM CEREBRAL ENDOTHELIUM
CD 36
ICAM 1
ROSSETING
ROSSETING
ADHERENCE
JAUNDICE
RENAL FAILURE CEREBRAL MALARIA
 
SEQUESTRATION 
 Through the process of Rosetting and cytoadherence the infected RBCs 
are trapped within micrvasculature of internal organs. This is called as 
sequestration. Sequestration leads on to microcirculatory obstruction which 
results in reduced oxygen & nutrient supply to tissues there by causing 
anaerobic glycolysis and lactic acidosis. 
PATHOGENESIS 
1. JAUNDICE 
• Hemolysis & increased Bilirubin production. 
• Hepatocyte injury due to ischemic damage caused by 
microcirculatory block. 
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• Cholestasis is major factor leading on to jaundice in malaria. 
Cytokines inhibits the active excretion of conjugated bilirubin 
into the biliary canaliculai. So the bilirubinemia is predominantly 
direct with very mild elevation of transaminases. 
JAUNDICE
HEMOLYSIS
ISCHEMIC HEPATITIIS
CHOLESTASIS
MINOR MAJOR
TNF & IL  INHIBITS ACTIVE EXCRETION
OF CONJUGATED  BILIRUBIN
CONJUGATED BILIRUBINEMIA WITHOUT MUCH 
ELEVATION OF SAP/ BS/ BP.
 
 
 
 
 
2. RENAL FAILURE 
• Microcirculatory (vasa recta ) block leading on to ischemic ATN. 
• Renal hypoperfusion due to shock secondary to vasodilatation 
caused by cytokines. 
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• Hemoglobinuria and Bilirubinuria in Black Water Fever can 
precipitate ATN. 
 
 
 
 
 
 
 
 
3. CEREBRAL MALARIA 
• Increased production of Nitric Oxide by cerebral endothelium 
induced by cytokines which inhibits neurotransmission. 
RBC 
PARASITATION 
ENDOTHELIAL ADHESION
ROSETTING 
CYTOADHERENCE 
HUMORAL 
FACTORS 
 
CATECHOLAMINES 
PG, KININS 
DIC
IMPAIRED TISSUE
PERFUSION
HYPOVOLEMIA
MONOCYTE  
ACTIVATION 
CYTOKINES VASOACTIVE
MEDIATORS
INTERSTITIAL
EDEMA
ARF 
INTRAVASCULAR
HEMOLYSIS 
HYPERBILIRUBINEMIA
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CYTOKINE HYPOTHESIS
MALARIAL TOXIN MACOPHAGE ACTIVATION
TNF alpha & IL - 6
UNCONTROLLED NITRIC OXIDE 
PRODUCTION
Nitric Oxide diffuse blood brain barrier
IMPAIRS SYNAPTIC TRANSMISSION
( like general anaesthetics / ethanol )
COMA
 
 
• Cerebral microcirculatory block leading on to anaerobic 
glycolysis and CSF lactic acidosis. 
• Mechanical hypothesis – increased bio mass of brain due to 
excessive RBC sequestration especially in children may cause 
deep coma and respiratory failure. 
 
 
 
 
  FLOW CHARTS SHOWING MECHANISMS OF CEREBRAL 
MALARIA 
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MECHANICAL HYPOTHESIS
SEQUESTRATION OF PfRBC & NON Pf RBC IN THE 
CEREBRAL CAPILLARIES & POST CAPILLARY  
VENULES
CYTOADHERANCE ROSSETING
MICROCIRCULATORY OBSTRUCTION
HYPOXIA
INCREASED CSF LACTATE
THERE IS NO THROMBUS / PLATLET ACTIVATION
AND NO COMPLETE OBSTRUCTION  
 
MECHANICAL HYPOTHESIS
INCREASED RBC IN CEREBRAL CIRCULATION
BIOMASS OF BRAIN
( NO CEREBRAL EDEMA)
DEEP COMA
RESPIRATORY FAILURE
 
 
 
4. COAGULOPATHY & THROMBOCYTOPENIA 
• Thrombocytopenia -   Increased destruction of platelets 
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      Decreased synthesis of platelets 
      Increased consumption in DIC 
• Prolongation of PT/ aPTT -  increased consumption of clotting 
factors due to DIC & decreased production by liver. 
 
5.     ANEMIA 
1. Destruction of parasitized RBCs. 
2. Accelerated destruction of non parasitized RBCs. 
3. Dys Erythropoiesis. 
 
6. PULMONARY EDEMA 
• Increased permeability of  alveolar capillary endothelium. 
 
7. HYPOGLYCEMIA 
• Increased peripheral utilization of glucose due to anaerobic 
glycolysis. 
• Parasite consumption in hyperparasitemia. 
• Failure of hepatic gluconeogenesis and glycogenolysis. 
• Quinine induced insulin secretion from pancreatic Beta cells. 
 
 
8.  GIT DYSFUNCTION 
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• Gut sequestration and visceral vasoconstriction leads on to 
malabsorption. This may increase the GUT wall permeability 
leading on to decreased local defence against bacterial invasion. 
 
9. LACTIC ACIDOSIS 
• Tissue anaerobic glycolysis due to microcirculatory block. 
• Decreased hepatic and renal clearance. 
• Increased lactate production by parasites. 
 
CO INFECTION OF VIVAX AND FALCIPARUM 
 When vivax and falciparum infects same individual at same time usually 
they don’t produce any complications. In vivo, vivax inhibits falciparum and 
vice versa. So contrary to belief mixed infections are benign.3 
 
CLINICAL FEATURES 
 Incubation periods of four species of plasmodium are different. Clinical 
features of uncomplicated malaria are common for all four species and are 
nonspecific. Headache, myalgia, vague abdominal discomfort, lethargy and 
lassitude often precede fever by up to 2 days. The temperature rises erratically 
at first with shivering, mild chills, worsening headache, malaise and decreased 
appetite. If left untreated fever in PV & PO regularizes to a 2 day cycle (Tertian 
pattern) and plasmodium malariae regularizes to 3 day cycle (quartan pattern). 
plasmodium falciparum remains erratic for longer period and may never 
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regularize to a tertian pattern. In an acute paroxysm patient first feels intense 
headache and muscular discomfort followed by cold and shivering. The 
temperature rapidly climbs up to a peak of 39-41C, which is followed by 
profuse sweating. Some patients can have mild abdominal discomfort and 
diarrhea. 
 Vivax and ovale malaria have a tendency to relapse weeks or months 
after primary infection due to exo erythrocytic cycle (Hypnozoites). 
Plasmodium falciparum is the usual cause of recrudescent malaria and these 
tend to occur  2-4 weeks after treatment. There is no exo erythrocytic phase in 
falciparum. 
 Increased incidence of severe anemia and reduction in birth weight is 
reported in pregnancies from high endemic areas. Severe malaria has high 
mortality among pregnant woman compared to non pregnant woman. 
 
 DEFINITION OF SEVERE MALARIA BY WHO: The criteria of MODS 
in malaria are given below 
 
1. Renal failure:  Serum Creatinine > = 3mgs/dl 
      Urine out put < 400ml/24hrs or <12ml/hr 
 
2. Severe anemia:  Hemoglobin <5gms% 
                     Hematochrit <15% 
 
3. Cerebral malaria: Unarousable coma with peripheral parasitemia 
 
4. Pulmonary edema 
 
5. Hypoglycemia: Blood sugar <40mg/dl 
 
6. Shock:  Systolic BP <70mmhg (in adults) 
           <50mmhg (in children 1-5 years) 
 
7. Acidemia:  PH <7.35, HCO3 <15 mq/L 
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8. Spontaneous bleeding: gums, nose and GIT due to DIC 
 
9. Macroscopic hemoglobinuria 
 
10. Seizures: More than two episodes 
 
11. Hyperparasitemia: More than 20% 
 
12. Jaundice: serum Bilirubin > 3mgs/dl-marker of severe malaria only when 
combined with other vital organ dysfunction (cerebral malaria and renal 
failure) 
 
 
 Impaired consciousness of any degree, jaundice, intractable vomiting 
and parasitemia > 2% in non immune individuals should be managed as severe 
malaria. 
 
CEREBRAL MALARIA 
 Defined strictly as unarousable coma not attributable to any other cause 
in a patient with plasmodium falciparum. Coma should persists for at least 30 
minutes after generalized convulsions. In practice any patient with fever and 
altered sensorium should be treated as severe malaria. The onset of coma may 
be sudden following a generalized convulsion or gradual with drowsiness, 
confusion, disorientation, delirium or agitation. There is no neck rigidity or 
other signs of meningeal irritation. Neurological manifestations are of 
symmetrical encephalopathy and focal signs are very rare. Untreated cerebral 
malaria is uniformly fatal (mortality 15% in children, 20% in adults and 50% in 
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pregnant woman). Post neurological syndromes occurs in 3% of adults and 
10% of children. They are persistent neurological deficit, psychosis, tremor and 
cerebellar dysfunction. Neurological deficit may be permanent in one fourth of 
cases.  
 
HEPATIC DYSFUNCTION 
 Usually of direct bilirubinemia with mild elevation of transaminases is 
noted. Hepatic failure and encephalopathy are very rare. If hepatic dysfunction 
is severe prothrombin time may be prolonged. 
 
ACUTE RENAL FAILURE 
 Usually occurs in adults in areas of low or unstable transmission. Patient 
may be oliguric or sometimes polyuric. In the fulminant form it is associated 
with hepatic dysfunction, metabolic acidosis and pulmonary edema. ARF may 
be associated with hemoglobinuria in patients with massive hemolysis.  
 
ANEMIA 
 Hemoglobin concentration may fall up to 2 g/dl each day. It is a problem 
in children which may lead on to high out put cardiac failure (Hb < 4 g/dl). 
 
 
 
METABOLIC ACIDOSIS 
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 Kusmaal’s breathing suggest metabolic acidosis. This may be due to 
Lactic acidosis caused by increased anaerobic glycolysis and acute renal 
failure. 
 
BLACK WATER FEVER 
 This is due to excessive intravascular hemolysis and hemoglobinuria. 
Hemoglobin in acidic urine gives black colour to urine. Massive 
hemoglobinuria leads on to ATN & renal failure. Now a days black water fever 
is very rare, if occurs it is usually transient and recovers spontaneously. 
 
ACUTE PULMONARY EDEMA 
 This is a type of Adult Respiratory distress syndrome and may develop 
at any time in severe plasmodium falciparum malaria. Severe breathlessness 
and hypoxemia are the main features. 
 
SECONDARY INFECTION 
 Since malaria is a state of transient immune suppression they are 
particularly vulnerable for respiratory infection, urinary tract infection and 
salmonella bacteremia.3 
 
 
 
DIAGNOSIS OF MALARIA 
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 Light microscopy – Thin and Thick Smear 
•  Cost effective, fairly sensitive & highly specific. 
• Thin smear is used for quick diagnosis and thick smear 
used for species identification. 
•  False negative - Very low parasitemia , sequestration 
of parasitised RBC, technical error. 
• False positive  - in highly endemic areas. 
 
  QBC for malaria (Quantitative Buffy Coat ) 
 Nuclear material of parasite (DNA& RNA) stained with 
fluorescent dyes and visualized under UV light 
microscopy. When blood in specialized capillary tube 
containing acridine orange stain and a float centrifuged, 
the infected RBC, which have a higher buoyant density 
than uninfected cells, become concentrated around the 
float. Sensitivity equal or slightly more than thick smear. 
 
  Paracheck- F ( Dipstick method)   
  Detects falciparum specific HRP released from RBCs 
using monoclonal antibody. 
 Simple and rapid. 
 
  OptiMAL – Parasite specific LDH detection 
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  Sensitivity – 92 to 98% 
  Specificity -  92 %  
 
  Polymerase chain reaction  
  Highly sensitive 
 Costly and not available easily 
 
LABORATORY ABNORMALITIES 
1. Hemogram – Anemia (Normochromic Normocytic Anemia) 
- Leucocytosis > 12,000 may be there. 
 
2.    Coagulopathy – Platelets < 50,000 – 100,0000 
   PT, a PTT may be prolonged 
   Fibrinogen > 200 mg/dl 
3.     Blood sugar, urea and creatinine. 
4.     LFT – Total Bilirubin, direct Bilirubin, SGOT, SGPT, SAP. 
5.     Arterial Blood Gas analysis to see for Acidosis 
6.     Chest X Ray – ARDS/ LRI 
7.     Ultrasound Abdomen – Hepatosplenomegaly. 
 
 
 
MANAGEMENT 
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  Apart from supportive management like adequate hydration and              
antipyretics the management strategy for complicated  and uncomplicated 
malaria are different. Once organ dysfunction is noted aggressive management 
is must to prevent morbidity and mortality. 
 UNCOMPLICATED MALARIA 
 Infection due to PV,PO and PM should be treated with oral chloroquine 
to a total dose of 25 mg/kg ( 10mg/kg followed by 5mg/kg 6hrs later and daily 
for two days) over three days. Plasmodium Falciparum should be considered as 
chloroquine resistant unless the sensitivity is proved and should be treated with 
Sulfadoxine 1500mg + pyrimethamine 75mg single dose or quinine 10mg 8th 
hrly with Doxycycline for 5 – 7 days. Mefloquine can also be used to a total 
dose of 25mg/kg (15mg/kg stat followed by 10mg/kg 12 hrs later). Mefloquine 
should be combined with Artesunate or artemether for 3 days. Quinine is bitter 
and may lead on to chinconism. Doxycycline and tetracycline should not be 
used in pregnancy and children less than 8yrs of age. 
 To eradicate persistent liver stages and to prevent relapse radical 
treatment is given in the form of Primaquine 15mg od for 14 days in 
plasmodium vivax and plasmodium ovale malaria. 
  Multi drug resistant Plasmodium Falciparum malaria can be treated with 
quinine, mefloquine, Artemether 20mg+Lumifantrine 120mg total of 6 doses 
and Atavoquine250mg+proguanil 100mg 4 tablets for 3 days. 
 
COMPLICATED MALARIA 
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 Because of widespread resistance, chloroquine can no longer be relied 
upon for treatment of severe malaria. Intravenous quinine remains the drug of 
choice in complicated malaria. Quinine should be given as loading dose of 
20mg/kg in D5 or D10 over 4 hrs and the repeated at dose of 10mg/kg in D5 
over 4 hrs 8th hrly. Once patient is able to take orally quinine should be given 
orally in the same dosage to a total of 5 – 7 days. Patient should be monitored 
for QTc prongation, hypoglycemia and Hypotension during intravenous 
quinine therapy. In severe renal failure quinine dose should be reduced to half 
after first 48 hrs. 
 Alternative therapy for complicated malaria are quinidine gluconate 
10mg/kg over 1-2 hrs followed by 0.02mg/kg/min, Artesunate 2.4mg/kg IV 
followed by 1.2mg/kg daily and Artemether 3.2mg/kg IM followed by 
1.6mg/kg/day for 3-5 days. 
 
 
 
 
 
 
 
 
 
    MALARIA: INDIAN SCENARIO 
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  In 1953 National Malaria Control Programme was launched to 
curb the menace of  malaria which mainly involved spraying of DDT to control 
the vectors. Due to overwhelming response with a drastic reduction of malaria 
cases to just 2 lakh cases in the year 1958 NMCP was converted to National 
Malaria Eradication Programme aimed at eradicating malaria from India. 
NMEP got a set back in sixties as the incidence of malaria cases was rising 
alarmingly due to widespread resistance of vector to DDT. With the 
implementation of Modified plan of operation in 1977, the upsurge of malaria 
cases dropped down from 6.74 million in 1976 to 2.1 million cases in 1984. 
Since 1997, there is a declining trend in annual malaria incidence from 3 
million in 1996 to 1.65 million in 2003 with 1000 deaths reported annually( 
gross under estimate).2 
 The major endemic areas in India are North East states, Orissa, 
Rajasthan, Andhrapradesh, Madhya Pradesh, Gujarat, Jharkand and 
Chathisgarh. In states like Orissa, Rajasthan and NE states the incidence of PF 
malaria is increasing at alarming rate especially chloroquine resistant strains. 
Over all the parasite profile is changing in India with chloroquine resistant PF 
malaria contributing to more than 50% of cases. Tamil Nadu is a low endemic 
area which had reported 43,382 cases in 2003 out of which 70% occurred in 
Chennai.2 Parasite profile in Chennai was 94.6% PV and 5.4% PF as per 
corporation of Chennai data. 
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 Recent study from Rajasthan, by Kochar , had revealed a major shift in 
clinical presentation and complications  of falciparum malaria. In 1994 cerebral 
malaria was the commonest complication encountered and also the commonest 
cause of death in PF malaria where as in 2001 jaundice , anemia, renal failure 
and MODS were the commonest presentation of severe malaria and cause of 
death. This  statistically significant shift in presentation of severe malaria from 
a solitary complication of cerebral malaria in 1994 to MODS in 2001 should 
alert the physician regarding diagnosis of severe  malaria when a patient 
presents with fever with Jaundice and Renal failure.8 
MAJOR SHIFT IN PRESENTATION OF FALCIPARUM MALARIA 
     1994 (in %)      2001 ( in %) 
• Jaundice   11.47   58.85 
• Anemia   5.83   26.04 
• Bleeding   9.59   25.54 
• MODS   9.59   22.40 
• Shock    5.26   10.94 
• Cerebral malaria  25.75   10.94  
• Black water fever  7.89   6.77 
• Renal failure  2.07   6.25 
• Thrombocytopenia  0.75   5.73 
• ARDS   3.01   2.08 
• GCTS   2.84   1.56 
 32
• Hypoglycemia  2.07   1.56 
 
 When ever severe complications are noted in plasmodium vivax malaria 
, it is attributed to undetected associated Falciparum malaria. But co infection 
of PV and PF inhibits each other in vivo and tends to be benign without any 
complications. Kochar et el in their study of 11  complicated vivax cases with 
jaundice, renal failure, cerebral malaria , ARDS and bleeding showed the 
presence of Plasmodium vivax in these patients and confirmed the absence of 
plasmodium falciparum by doing genetic study (PCR). This study shows that 
vivax can also produce complications.9 
 In a study of 441 cases of cerebral malaria Kochar et al reported various 
clinical presentations and post cerebral malaria neurological sequelae as 
follows:10 
CEREBRAL MALARIA IN INDIAN ADULTS –  
A STUDY OF 441 CASES AT BIKANER, NORTH WEST INDIA  
CLINICAL PRESENTATION 
 Fever   - 100% 
Unconsciousness  - 100% 
Fits    - 21.31% 
Neck rigidity  - 19% 
Psychosis   - 5.21% 
Conjugate Eye deviation - 2.26% 
Extrapyramidal rigidity - 2.25% 
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Trismus   - 1.31% 
Decorticate rigidity - 1.13% 
Decerebrate rigidity - 0.90% 
 
 They have reported a mortality of 32.37% in cerebral malaria in adults. 
The commonest neurological sequelae  noted were cerebellar ataxia (6.74%), 
psychosis (5.05%) and aphasia (5.7%). Other associated complications noted in 
cerebral malaria patients were severe anemia (6.8%), jaundice (6.8%), renal 
failure (9.07%) and hypoglycemia (4.08%).10 
 Hazra et al reported various clinical profile of malaria in their study of 
225 cases (165PV and 60PF ) from Calcutta as follows:11 
 
Clinical features Plasmodium Vivax 
(n-165) 
 Plasmodium 
Falciparum (n – 60) 
Classic paroxysm 42.27% 40% 
Continuous fever 27.2% 40% 
Jaundice 9.09% 40% 
Splenomegaly 18.18% 40% 
Renal failure - 5% 
ARDS - 6.6% 
GCTS/Coma - 8.3% 
DIC - 3.3% 
Black water fever - 3.3% 
 
 
Mohapatra et al from Berhampur has reported various atypical presentations of 
malaria, in their study of 110 cases of vivax malaria. They were absence of 
malarial paroxysm(22.8%), migrainous headache (4.5%), myalgia (6.3%), 
episodic urticarial rash (1.8%), relative bradycardia (13.6%) & postural 
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hypotension (2.7%). They also noted complications like Jaundice (7.2%), 
Cerebral malaria (0.9%), severe anemia (7.2%) and thrombocytopenia 
(3.6%).12 
 The incidence of ARF in malaria is estimated to vary from 1 – 60%. In 
India, the incidence reported is 17.8% from Delhi, 17.2% from Orissa, 13% 
from North East India and 5.9% from Mumbai.13 Profile of ARF in India 
suggests that malaria contributes 38% of ARF in Orissa and 15.5% in East 
India (with a increase from 6.6 % in 1995 to 27% in 1999).14 In Chennai there 
were no reports of ARF due to malaria before 1995 but since then it has 
become an important cause of ARF . Jeyakumar et al has reported a incidence 
of 4.5% malarial ARF in their study of 1112 patients of ARF in Chennai.15 
Plamodium falciparum is the common cause of malarial ARF though also 
reported with vivax. Prakash et al reported 16.1% of malarial ARF among 577 
ARF cases studied, out of which 79.6% is due to PF and 20.4% due to PV.16 
Mehta KS et al from mumbai reported a incidence of 5.9% ARF in their study 
of  402 cases of malaria  87.5% due to PF and 13.5% caused by PV.17 
 Thus malaria still remains to be a major public health problem in India. 
The rise in chloroquine resistant strains of Falciparum and the shift in 
presentation of severe malaria from cerebral malaria to multiple organ 
dysfunction should alarm the medical authorities and the public health 
authorities to take necessary steps to control malaria effectively.  
 
 
 35
 
PATIENT AND METHODS 
 
 
1. Patients with fever, from north Chennai  admitted to Stanley medical 
college hospital who were tested positive for plasmodium vivax / 
falciparum by peripheral smear study (Giemsa ) / QBC ( Quantitative 
Buffy Coat) were taken up for the study. 
2. All the patients were evaluated for : 
 a. Clinical features 
• Intermittent paroxysm 
• Head ache 
• Chills 
• Vomiting 
• Diarrhea 
• Icterus  
• Hepatosplenomegaly 
• Loss of consciousness 
• Convulsions 
• Altered behaviour 
 b. Laboratory  parameters 
• Hemogram – Hb,TLC, DLC, platelet count, 
• Renal function – Serum urea, creatinine & electrolytes. 
• Blood sugar 
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• Liver function tests – Total bilirubin, Direct bilirubin, 
SGOT,SGPT & SAP. 
• ECG – to rule out any cardiac abnormality for quinine 
administration 
• Chest X -  ray 
 
 3. EXCLUSION CRITERIA 
  Patients with leptospirosis, enteric fever and hepatitis were 
excluded by doing appropriate investigations. Patients co infected by both 
plasmodium vivax and falciparum were also excluded from the study.  
 
4. Following criteria were taken to define organ dysfunction in severe malaria: 
• Severe anemia - Hb < 8g/dl 
• Renal failure  - Sr Creatinine - 1.5- 3 mg/dl (mild) 
      Sr Creatinine  > 3 mg/dl ( severe ) 
• Jaundice  - Total Bilirubin – 1.5 -3 mg/dl (mild) 
      Total Bilirubin -  > 3 mg/dl (severe) 
• Cerebral malaria - Loss of Consciousness 
    - Altered behaviour / sensorium 
    - Generalized Convulsions with no  
     previous history of seizures 
• Thrombocytopenia  - Platelet count < 1 Lac 
• Hypoglycemia -  < 60 mg/dl 
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• ARDS   - SiO2 < 70% ( pulse oximeter) with 
CXR     findings and breathlessness 
 
5. Treatment strategy:  
• All uncomplicated malaria patients were treated with Chloroquine 
(25mg/kg ) with Doxycycline 100mg bd for 3 days. If there is no clinical 
response, these patients were switched over to quinine 10mg/kg 8th Hrly. 
• All complicated malaria patients showing organ dysfunction were 
started on quinine 10mg/kg 8th hrly oral or intravenously in dextrose 
solution along with oral Doxycycline 100mg bd for 7 days. 
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RESULTS : Total  of 250 patients were analysed and the results were : 
 
TOTAL NUMBER OF PATIENTS - 250 
 
NUMBER OF PV    - 210 (84%) 
 
NUMBER OF PF    - 40 (16%) 
 
NUMBER OF MALES   - 170 (68%) 
 
NUMBER OF FEMALES  - 80 (32%) 
 
     
     TABLE  - 1 
  
         AGE AND SEX DISTRIBUTION 
 
 
 
Plasmodium Vivax 
(n – 210) 
 
 
Plasmodium falciparum 
(n-40)% 
 
 
AGE 
RANGE 
In YRS  
MALE 
 
FEMALE 
 
MALE 
 
FEMALE 
 
 
 
 
TOTAL 
13 – 20 50 15 3 2 70 ( 28%) 
21 - 30 37 20 7 4 69 (27.6%) 
31- 40 16 12 4 3 36 (14.4%) 
41 - 50 17 7 5 3 33 (13.2%) 
51 - 60 10 2 3 1 16 (6.4%) 
61 - 70 10 7 3 1 21 (8.4%) 
> 71 5 2 0 1 8  (3.2%) 
 
TOTAL 
 
 
145( 69%) 
 
65(31%) 
 
25 (62.5%) 
 
15(37.5%) 
 
250 
 
 
MEAN AGE - 27.7 Yrs       (RANGE - 13 TO 82 Yrs) 
 
About 70% of patients were in the age group of 13 to 40 years of age. 68% 
were males and 32% were females. 
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    ` TABLE-2  
 SEASONAL INCIDENCE IN OCCURANCE OF MALARIA 
 
More than 50% of cases occurred during June and December 2005 which well 
correlate with monsoon in Chennai.    
  
 
 
 
 
MONTH, 
YEAR 
 
PLASMODIUM 
VIVAX 
(n-210)  
 
PLASMODIUM 
FALCIPARUM 
(n-40) 
 
TOTAL 
(n-250)% 
May 2005 16 02 18 (7.2%) 
Jun 2005 23 06 29 (11.6%) 
Jul 2005 20 02 22 (8.8%) 
Aug 2005 13 02 15 (6%) 
Sep 2005 19 03 21 (8.4%) 
Oct 2005 22 05 27 (10.8%) 
Nov 2005 19 12 31 (12.4%) 
Dec 2005 10 0 10 (4%) 
Jan 2006 06 0 O6 (2.4%) 
Feb 2006 09 0 09 (3.6%) 
Mar 2006 06 02 08 (3.2%) 
Apr 2006 08 03 11 (4.4%) 
May 2006 10 0 10 (4%) 
Jun 2006 15 02 17 (6.8%) 
Jul 2006 14 01 15 (6%) 
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 BAR CHART SHOWING SEASONAL VARIATION  
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  2005      2006 
  
Bar chart showing occurrence of malaria during monsoon and post monsoon in 
Chennai. 
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TABLE - 3 
 
CLINICAL PROFILE OF PV AND PF MALARIA 
  
 
 
CLINICAL 
FEATURES 
 
 
PLASMODIUM
VIVAX 
 (n-210) % 
 
PLASMODIUM 
FALCIPARUM  
(n-40)% 
 
TOTAL 
 
(n-250)% 
 
FEVER 
 
210 (100%) 
 
40 (100%) 
 
250(100%) 
 
CHILLS 
 
183 (87%) 
 
33 (82%) 
 
216 
(86.4%) 
 
HEADACHE 
 
152 (72%) 
 
32 (80%) 
 
184 
(73.6%) 
 
MYALGIA 
 
45 (21%) 
 
09 (23%) 
 
54 (21.6%) 
 
VOMITING 
 
80 (38%) 
 
23 (58%) 
 
103(41.2%)
 
DIARRHEA 
 
07 (3%) 
 
01 (2%) 
 
08 (3.2%) 
 
ICTERUS 
 
11 (5%) 
 
17 (43%) 
 
28 (11.2%) 
 
SPLENOMEGALY 
 
44 (21%) 
 
15 (33%) 
 
59 (23.6%) 
 
HEPATOMEGALY 
 
18 (9%) 
 
06 (15%) 
 
24 (9.6%) 
 
LOC 
 
25 (12%) 
 
05 (13%) 
 
30 (12%) 
 
CONVULSION 
 
14 (7%) 
 
02 (5%) 
 
16 (6.4%) 
 
 
 
Fever occurred in all patients . Chills and headache were the commonest 
associated symptoms in more than 80% of the patients. Icterus and 
splenomegaly occurred more commonly in PF cases than in PV. 
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     TABLE  - 4 
 
   JAUNDICE : SERUM BILIRUBIN 
 
 
    TOTAL 
BILIRUBIN 
mg/dl 
 
 
PLASMODIUM 
VIVAX 
(n-210) % 
 
PLASMODIUM 
FALCIPARUM 
(n-40)% 
 
TOTAL 
 
(n-250)% 
 
1.5 – 3 
(Our Criteria ) 
 
12 (5.7%) 
 
11(27.5%) 
 
23 (9.2%) 
 
> 3 
(WHO Criteria) 
 
12 (5.7%) 
 
08 (20%) 
 
20 (8%) 
 
TOTAL 
 
 
24 (11.4%) 
 
19 (47.5%) 
 
43 (17.2%) 
 
 
MEAN BILIRUBIN - 5.3 mg/dl  (RANGE  1.5 – 22) 
 
 
     TABLE  - 5 
 
    TRANSAMINASES : SGOT 
 
 
SGOT IU/L 
 
 
PLASMODIUM
VIVAX 
(n-24) 
 
PLASMODIUM 
FALCIPARUM 
(n-19) 
 
TOTAL 
 
(n-43)% 
 
< 40 
 
06 
 
 
02 
 
08 (18.6%) 
 
40 - 80 
 
12 
 
 
09 
 
21 (48.8%) 
 
> 80 
 
06 
 
 
08 
 
14 (32.6%) 
 
 
MEAN SGOT - 82.67 IU/L   (Range 17 – 238) 
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TABLE - 6 
 
TRANSAMINASES: SGPT 
 
 
 
 
SGPT IU/L 
 
PLASMODIUM
VIVAX 
(n-24) 
 
PLASMODIUM 
FALCIPARUM 
(n-19) 
 
TOTAL 
 
(n-43)% 
 
< 40 
 
04 
 
 
02 
 
06 (14%) 
 
40 - 80 
 
13 
 
 
10 
 
23 (53.5%) 
 
> 80 
 
07 
 
 
07 
 
14 (32.5%) 
 
 
 
MEAN SGPT -  82.86 IU/L ( Range 16 – 400 ) 
 
 
 
 
Jaundice occurred in 17.2% of cases and its more common in Falciparum 
malaria (47.5%) than in Vivax malaria (11.4%). Maximum Bilirubin noted was 
22 mg/dl. More than half of these patients had mild elevation in transaminases 
in the range of 40 to 80 IU/L. 
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A PATIENT WITH JAUNDICE AND RENAL FAILURE IN VIVAX 
MALARIA 
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TABLE  - 7 
 
RENAL FAILURE : SERUM CREATININE 
 
 
 
SERUM 
CREATININE 
mg/dl 
 
PLASMODIUM 
VIVAX 
(n-210) % 
 
PLASMODIUM 
FALCIPARUM 
(n-40)% 
 
TOTAL 
 
(n-250)% 
 
1.5 – 3 
(Our Criteria ) 
 
12 (5.7%) 
 
 
07 (17.5%) 
 
19 (7.6%) 
 
> 3 
(WHO Criteria) 
 
04 (1.9%) 
 
 
03 (7.5%) 
 
07 (2.8%) 
 
TOTAL 
 
16 (7.6%) 
 
 
10 (25%) 
 
26 (10.4%) 
 
MEAN  CREATININE -   2.6 mg / dl (Range 1.5 – 6.4 ) 
      
 
               TABLE  - 8 
 
            RENAL FAILURE : SERUM UREA 
 
 
 
UREA 
mg/dl 
 
PLASMODIUM 
VIVAX 
(n-16) 
 
PLASMODIUM 
FALCIPARUM 
(n-10) 
 
TOTAL 
 
(n-26) 
 
< 40 
 
0 
 
0 
 
0 
 
40 - 80 
 
07 
 
04 
 
11 (42.3%) 
 
> 80 
 
09 
 
06 
 
15 (57.7%) 
 
MEAN UREA -   99.5 mg / dl (Range 42 – 200 ) 
      
Renal failure occurred in 10.4 % of cases as per our criteria but by WHO 
criteria its only 2.8%. Maximum Creatinine and urea noted was 6.4 mg/dl and 
200 mg/dl. 
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TABLE - 9 
 
 
CEREBRAL MALARIA 
 
 
 
SYMPTOMS 
 
PLASMODIUM 
VIVAX  
(n-210) % 
 
PLASMODIUM 
FALCIPARUM 
(n-40)% 
 
TOTAL 
 
 (n-250)% 
 
LOC 
 
 
13 
 
04 
 
17 
 
GCTS & LOC 
 
12 
 
01 
 
13 
 
 
GCTS 
 
 
02 
 
01 
 
03 
 
TOTAL 
 
 
27(12%) 
 
06(15%) 
 
33(13.2%) 
 
 
 
TOTAL CEREBRAL MALARIA  –  33 
 
TOTAL LOC    - 30 (90.9%) 
 
TOTAL GCTS    - 16 (48.5%) 
 
 
 
 
Cerebral malaria occurred in 13.2% of cases. 90.9% of them had altered level 
of consciousness or altered behaviour where as generalized convulsions 
occurred in 48.5% of cases. 
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TABLE - 10 
 
ANEMIA 
 
 
 
HEMOGLOBIN 
g/dl 
 
PLASMODIUM 
VIVAX 
(n-210) % 
 
PLASMODIUM 
FALCIPARUM 
(n-40)% 
 
TOTAL 
 
(n-250)% 
 
8 – 10 
 
 
72 (34.3%) 
 
10 (25%) 
 
82 (32.8%) 
 
5 – 8 
(Our Criteria) 
 
28 (13.3%) 
 
09 (22.5%) 
 
37 (14.8%) 
 
< 5 
( WHO Criteria) 
 
01 (0.4 %) 
 
02 (5%) 
 
03 (1.2%) 
 
TOTAL 
 
 
101 (48.1%) 
 
21 (52.5%) 
 
122 (48.8%) 
 
 
 
MEAN HEMOGLOBIN - 8.5g/dl 
 
 
RANGE   - 4.6 TO 10 g/dl 
 
 
 
 
 
 
48.8% of cases had hemoglobin less than 10 g/dl. As per our criteria anemia 
occurred in 16% of  cases where as by WHO criteria it is only 1.2%. the lowest 
hemoglobin noted was 4.6 g/dl. 
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COMBINATION OF COMPLICATIONS 
 
TABLE - 11 
 
ANEMIA WITH OTHER ORGAN DYSFUNCTION 
 
ANEMIA 
 Hb < 8g/dl  
WITH 
 
PLASMODIUM 
VIVAX 
(n-29) 
 
PLASMODIUM 
FALCIPARUM    
(n-11) 
 
TOTAL 
(n-40) 
 
 
RENAL 
FAILURE 
Sr Cr > 1.5 mg/dl 
 
02 
 
06 
 
08 (20%) 
 
JAUNDICE 
TB > 1.5 mg/dl 
 
04 
 
09 
 
13 (32.5%) 
 
CEREBRAL 
MALARIA 
 
05 
 
03 
 
08 (20%) 
 
Jaundice is the commonest complication associated with anemia which 
occurred  in 32.5% of cases    
     TABLE - 12 
 
  JAUNDICE WITH OTHER ORGAN DYSFUNCTION 
 
Renal failure was the commonest complication associated with Jaundice. 
 
 
 
 
 
JAUNDICE 
WITH  
(TB > 1.5 mg/dl) 
 
PLASMODIUM 
VIVAX 
(n-24) 
 
PLASMODIUM 
FALCIPARUM 
(n-19) 
 
TOTAL 
 
(n-43)% 
 
ANEMIA 
 Hb < 8g/dl 
 
04 
 
09 
 
13 (30.2%) 
RENAL 
FAILURE 
Sr Cr > 1.5 mg/dl 
 
05 
 
09 
 
14 (32.5%) 
 
CEREBRAL  
MALARIA 
 
06 
 
04 
 
10 (23.3%) 
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     TABLE - 13 
 
 CEREBRAL MALARIA WITH OTHER ORGAN DYSFUNCTION 
 
Jaundice was commonly associated with cerebral malaria patients in 30.3%.  
 
     TABLE – 14 
 
  RENAL FAILURE WITH OTHER ORGAN DYSFUNCTION 
Jaundice is the commonest complication associated with renal failure which 
occurred in 53.8% of cases. 
    
 
 
   
 
CEREBRAL 
MALARIA 
WITH 
 
PLASMODIUM 
VIVAX 
(n-27) 
 
PLASMODIUM 
FALCIPARUM 
(n-06) 
 
TOTAL 
 
(n-33) 
 
ANEMIA 
 Hb < 8g/dl 
 
05 
 
03 
 
08 (24.2%) 
 
RENAL 
FAILURE 
Sr Cr > 1.5 mg/dl 
 
06 
 
03 
 
09 (27.3%) 
 
JAUNDICE 
TB > 1.5 mg/dl 
 
06 
 
04 
 
10 (30.3%) 
 
RENAL 
FAILURE 
Sr Cr > 1.5 mg/dl 
WITH 
 
PLASMODIUM 
VIVAX 
(n-16) 
 
PLASMODIUM 
FALCIPARUM    
(n-10) 
 
TOTAL 
(n-26)% 
 
 
ANEMIA 
 Hb < 8g/dl 
 
02 
 
06 
 
08 (30.8%) 
 
JAUNDICE 
TB > 1.5 mg/dl 
 
O5 
 
09 
 
14 (53.8%) 
 
CEREBRAL 
MALARIA 
 
06 
 
03 
 
09 (34.6%) 
 51
TABLE - 15 
COMPLICATIONS 
 
 
COMPLICATIONS 
 
 
TOTAL 
(n-250)%
 
PV 
(n-210) % 
 
PF 
(n-40)% 
Significan
ce 
P value 
 
ANEMIA Hb < 8g/dl   
WITH 
 
40  
(16%) 
 
29 
 (13.8%) 
 
11  
(27.5%) 
 
0.03 
 
JAUNDICE 
TB > 1.5 mg/dl 
 
43 
(17.2%) 
 
24  
(11.4%) 
 
19 
 (47.5%) 
 
0.001 
 
RENAL FAILURE 
Sr Cr > 1.5 mg/dl 
 
26 
(10.4%) 
 
16 
 (7.6%) 
 
10 
 (25%) 
 
0.001 
 
CEREBRAL 
MALARIA 
 
33 
(13.2%) 
 
27 
(12%) 
 
06 
(15%) 
 
0.7 
 
THROMBOCYTOPENIA
(PLATELET < 1 Lac) 
 
04  
(1.6%) 
 
O2  
(0.9%) 
 
02 
 (5%) 
 
0.06 
 
ARDS  
SiO2 < 70% 
 
03  
(1.2%) 
 
02  
(0.9%) 
 
01  
(2.5%) 
 
0.41 
 
ALGID MALARIA/ 
HYPOTENSION 
 
08 
 (3.2%) 
 
07  
(3.3%) 
 
01 
 (2.5%) 
 
0.78 
 
CORTICAL VENOUS 
THROMBOSIS 
 
03  
(1.2 %) 
 
03  
(1.4%) 
 
0 
 
0.44 
 
HYPOGLYCEMIA 
PL GLUC < 60 
 
04  
(1.6%) 
 
02  
(0.9%) 
 
02  
(5%) 
 
0.06 
 
 In falciparum malaria renal failure and jaundice is more common than cerebral 
malaria. The difference in incidence of jaundice and renal failure in PV & PF is 
statistically significant (p value 0.001) and there is no significant difference in 
incidence of other complications. 
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COMPARISON BAR CHARTS OF COMPLICATION IN PV & PF  
   COMPLICATION IN VIVAX MALARIA 
13.8%
11.4%
7.6%
12%
0.9% 0.9% 3.3% 1.4% 0.9%
0
10
20
30
40
50
A J RF CM TH AR AM C HY
  
  COMPLICATION IN FALCIPARUM MALARIA 
27.5%
47.5%
25%
15%
5% 2.5% 2.5% 0
5%
0
10
20
30
40
50
A J RF CM TH AR AM C HY
LEGENDS – A-Anemia, J -  jaundice, RF – Renal failure, CM – Cerebral 
malaria, TH – Thrombocytopenia, AR – ARDS, AM – Algid malaria, C – 
CVT, HY – Hypoglycemia. 
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TABLE – 16 
TREATMENT 
 
 
DRUGS 
 
PLASMODIUM 
VIVAX 
(n-210) % 
 
PLASMODIUM 
FALCIPARUM 
(n-40)% 
 
TOTAL 
(n-250)% 
 
CHLOROQUINE 
+DOXY 
 
100 (47.6%) 
 
06 (15%) 
 
106 (42.4%) 
 
QUININE 
+DOXY 
 
62 (29.5%) 
 
28 (70%) 
 
90 (36%) 
 
CHLORQUINE   
 
QUININE 
 
 
44 (20.9%) 
 
 
04 (10%) 
 
 
48 (19.2%) 
 
ARTEMISININ 
 
 
04 (1.9%) 
 
02 (5%) 
 
06 (2.4%) 
 
TOTAL NO. OF PATIENTS TREATED WITH CHLOROQUINE - 154  
 
NO. RESPONDED TO CHLOROQUINE    - 106 
(68.8%) 
 
NO. NOT RESPONDED (RESISTANT)    - 48 
(31.2%) 
 
 
ARTEMISISNIN IS USED AS QUININE WAS CONTRAINDICATED IN 06  
 
PATIENTS WHO HAD ISCHEMIC HEART DISEASE.  
 
Quinine is found to be very effective in complicated and chloriquine resistant 
malaria. 31.2% of patients showed chloroquine resistance. 
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     TABLE – 17 
             MORTALITY 
 
 
PLASMODIUM 
VIVAX 
(n-210) % 
 
PLASMODIUM 
FALCIPARUM 
(n-40)% 
 
TOTAL 
(n-250)% 
 
O3 (1.4%) 
 
01(2.5%) 
 
04 (1.6%) 
 
 
Mortality of 1.6% is noted. 3 patients had vivax and one Falciparum. The cause 
of death were cerebral malaria in one case and MODS in other three patients. 
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    DISCUSSION  
  In India, 2.5 to 3 million cases and 1000 deaths of malaria are reported 
annually.2 Many consider this is an underestimate. Areas with more than 30% 
of PF cases are categorized as high risk. These include North East India, 
Orissa, Jharkand, West Bengal, Madhya Pradesh, Maharashtra & 
Andrapradesh.  Tamil Nadu has reported 43,000 cases in 2003, out of which  
70% of cases were from Chennai.  Malaria is highly prevalent in places from 
North Chennai like Tondaiarpet, Washermanpet, Royapuram, Harbour, 
Mannady, Pattalam & Pulianthope. This study was undertaken at Stanley 
Medical college Hospital which is located in North Chennai. This study deals 
with clinical and laboratory profile of Malaria in North Chennai. 
 Total of 250 cases of Malaria admitted to Stanley Medical college 
hospital were analyzed. Plasmodium vivax occurred in 210 ( 84%) and 
plasmodium falciparum occurred in 40 (16%) patients. There were 170 (68%) 
males and 80 (32%) females. Mean age of presentation was 27.7 years (range 
13 to 82 years). About 70% of patients were in the age group of  13 to 40 years.  
The  parasitic profile noted was 84% PV & 16% PF where as the parasitic 
profile as per corporation of Chennai data is 94.6% PV & 5.4% PF . This 
difference is due to analysis of hospitalized patients in our study where only 
severely ill patients get admitted. Chennai corporation data is mainly from 
OPD cases. Hazra et al  from Calcutta has reported 73.3% PV & 26.7% PF in 
their study of 225 cases.11 Mehta et al from Orissa has reported 54.5% PV, 
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36.6% PF and  8.9% of mixed infection.16 This shows that the parasitic profile 
is different in various places. Thus Tamilnadu is in low risk category.   
 
CLINICAL FEATURES 
 100% patients had fever. Typical paroxysms occurred only in very few 
patients. Most of them had daily fever peaking once in a day. Fever was 
associated with chills in 86% of cases ( 87% of PV & 82% of PF). Head ache 
occurred in 73.6% of patients ( 72% of PV & 80% of PF). Head ache was 
severe and was consistently associated with onset of fever. Mohapatra et al 
from Orissa reported migrainous head ache of 4.5%  in a study of 110 cases of 
vivax Malaria.12 
 Vomiting(41.2%), Diarrhea (3.2%), Clinical jaundice(11.2%), 
Myalgia(21.6%), Diarrhea (3.2%), Hepatomegaly (9.6%) and Splenomegaly 
(23.6%) were the other clinical manifestations noted. 21% of PV and  33% of 
PF patients had Splenomegaly. This is consistent with Hazra et al study, who 
had reported Splenomegaly in 18.18% of PV and 40% of PF cases.11 Mohapatra 
et al had reported 6.3% of myalgia in their study of 110 cases of vivax 
malaria.12 
  In our study more than 50% of the cases occurred during June and 
December 2005 which well correlates with the monsoon season of Chennai. 
Maximum number of 31 cases were reported in the month of November 2005 
when Chennai was in floods. 
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JAUNDICE 
  Jaundice is the commonest complication noted in our study. Serum 
bilirubin of more than 1.5mg occurred in 43 cases (17.2%). As per WHO 
criteria serum Bilirubin of more than 3mg/ occurred only in 8% of cases.  
Serum Bilirubin ranged from 1.5 to 22mg/dl. Bilirubinemia is predominantly 
direct. Jaundice occurred in 11.4% of PV and 47.5% of PF cases. This is 
consistent with a study from Calcutta ,in which hazra et al reported jaundice in 
9.09% of  PV and 40%  of PF cases.11 Harris VK et al from south India 
reported 37% of jaundice in Pf cases.18 Kochar et al from Rajasthan has 
reported jaundice 58.85% of PF cases 2001. 8 
  In respect of hepatic enzymes, SGOT  was elevated in the range of 40-
80 IU /L  in 48.8% and more than 80IU/L in 32.6% of cases. Maximum SGOT 
level noted was 438 IU/L. 53.5% of  jaundiced patients showed  SGPT 
elevation in the range of 40-80 IU/L & 32.5% over 80IU/L. Nityanand  et al 
from Haryana has reported mean SGOT & SGPT of 120 & 130 IU/L 
respectively in their study of 60 cases.19 Kochar et al from Rajasthan has 
reported a range of SGOT & SGPT of 40-1120 IU/L and 40-1245IU/L 
respectively. 20 
      In our study the maximum Bilirubin noted was 22mg/dl, SGOT 483 IU/L 
and SGPT 400. Bilirubinemia is predominantly direct and in most of the cases 
there is only mild elevation of transaminases. Out of 43 jaundiced patients 30% 
had Anemia, 32.5% had Renal failure and 23.3% had cerebral malaria.  
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RENAL FAILURE 
 Acute renal failure occurred in 10.4% of cases (Serum Creatinine 
>1.5mg/dl). As per WHO criteria (Serum Creatinine >3 mg/dl) ARF occurred 
only in 2.8% of cases. In our study ARF occurred in 7.6% of PV and 25% of 
PF cases. Severe renal failure (Serum Creatinine >3mg/dl) occurred in 1.9% of 
PV and 7.5% of PF cases. This is consistent  with Kochar’s reported incidence 
of 6.25% of ARF in PF cases in 2001.8 Nityanand et al reported an incidence of 
21% ARF in a study of 60 cases (PV 14 and PF 46). 19 
 In our study it has been found that renal failure also occurs in PV 
malaria in significant numbers. This has been proved by Kochar in his study of 
11 cases of complicated Vivax malaria by documenting presence of PV and 
absence of PF by genetic study (PCR).9, 21, 22 
 57.7% of ARF patients showed rise in urea >80 mg/dl and remaining in 
the range of 40 to 80 mg/dl. Maximum Creatinine noted was 6.4 mg/dl and 
urea 200 mg/dl. No patient was dialysed. One patient with ARF died who also 
had other complications like jaundice, Anemia and ARDS. 
 In India reported incidence of ARF in malaria is 17.8% from 
Delhi,17.2% from Orissa, 13% from Northeast India and 5.9% from Mumbai.13 
Before 1995 there were no reports of ARF due to malaria in Chennai, Since 
then it has become an important cause of ARF which contribute to 4.5% of 
ARF.15 Prakash et al from Varanasi reported 93 cases (16.1%) ( 74 PF and 19 
PV) of Malarial ARF out of 577 cases of ARF studied.16 Other complications 
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noted among ARF patients were jaundice 53.8%, anemia 30.8% and cerebral 
malaria 34.6%. 
 
CEREBRAL MALARIA 
 33 patients (13.2%) had neurological dysfunction in the form of altered 
sensorium, loss of consciousness and generalized convulsions. 17 patients 
(51.5%) had LOC, 13 (39.3%) had both LOC and convulsions, and 3 (9%) had 
only convulsions. Kochar reported generalized convulsions in 21.31% of 441 
cases of cerebral malaria from Rajasthan.10 12.8% of PV and 15% of PF had 
cerebral malaria in our study. This is consistent with Kochar’s reported 
incidence of 10.9% of cerebral malaria in PF cases in 2001.8 Siginificant 
number of  PV patients exhibited neurological dysfunction.9  
  Other complications noted in cerebral malaria patients were anemia 
24.2%, renal failure 27.3% and raundice 30.3%. Kochar has reported 31.74% 
of jaundice, 9.09% of renal failure and 6.8% of severe anemia in his study of 
441 patients of cerebral malaria.10 One patient died due to cerebral malaria 
caused by plasmodium vivax. 
 
ANEMIA  
 48.8% of patients had Hb <10g/dl. Considering Hb <8g/dl as severe 
anemia the incidence is 16% and by WHO criteria (Hb <5g/dl) the incidence is 
only 1.2%. The lowest Hb noted in our study was 4.6g/dl. 13.7% of PV and 
27.5% of PF cases had Hb <8g/dl. This is consistent with Kochar’s repoted 
incidence of severe anemia in 26.04% of PF cases.8 Mean Hb noted was 
8.5g/dl. 
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 Other complications noted with severe anemia (Hb <8g/dl) were renal 
failure 20%, Jaundice 32.5% and Cerebral malaria 20%. 
 
OTHER COMPLICATIONS  
 Thrombocytopenia (platelet <1Lac) occurred in  4 cases (1.6%), 2 
(0.9%)in PV and 2 (5%) in PF. Kochar reported 5.7% of Thrombocytopenia in 
PF cases in 2001.8 
 ARDS developed in 3(1.2%) patients, 2(0.9%) in PV and 1(2.5%) in PF. 
All the 3 died. Kochar reported 3.01%of ARDS in PF cases in 2001.8 
  Algid malaria with profound hypotension occurred in 3.2% of cases, 
3.2% in PV and 2.5% in PF. Kochar reported 5.26% of shock  in PF cases in 
2001.8 
 Hypoglycemia occurred in 4 cases (1.6%),2 in PV(0.9%) and 2 (5%) in 
PF. Kochar reported 2.07%of hypoglycemia in PF cases in 2001.8 
 Cortical Venous thrombosis occurred in 3 patients of Vivax malaria. 
One male and two female (Post Partal Period) had CVT. There are very few  
data regarding complications occurring  in vivax malaria . 
 
MODS  
 In recent past the incidence of cerebral malaria is found to be declining 
and the complicated malaria, most commonly presents as multiple organ 
dysfunction. The usual combination were severe anemia, jaundice, renal failure 
and ARDS. In our study, commonest combination noted was renal failure with 
jaundice which had occurred in 14 patients (5 PV and 9 PF). Dreaded 
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combination of anemia, renal failure, jaundice and cerebral malaria occurred in 
2 patients ( 1 PV and 1 PF).  
 The WHO criteria for diagnosis of  organ dysfunction in severe malaria 
is serum Creatinine and Bilirubin of more than 3 mg / dl. We had taken a 
criteria of > 1.5 mg/dl  for early diagnosis of ARF and jaundice which would 
prompt aggressive management early and prevent mortality. 
 
MORTALITY 
 Four patients died which accounts for 1.6% of mortality rate. 3 had PV 
and 1 had PF. One patient with PV died of cerebral malaria and all the other 
three deaths were due to MODS with ARDS. This is consistent with Kochar’s 
findings of shift in cause of mortality from cerebral malaria to MODS (1994 to 
2001).8 Low mortality may be due to early detection of organ dysfunction and 
aggressive management.  
 
TREATMENT  
 In our study uncomplicated malaria patients were given chloroquine and 
if the fever persists after full course of chloroquine, Quinine was given. 42.4%  
(100 PV and 6 PF)  of cases responded to Chloroquine and Doxycycline. 36% 
(62 PV and 28 PF) of patients were started on quinine and Doxycycline as they 
had complications. In 48 patients, Chloroquine  was switched over to quinine 
as they showed no clinical response. There were no treatment failures with 
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quinine. Artemisinin group of drugs were used in 6 patients in whom quinine 
was contra indicated. 
 47.6% of Vivax malaria responded to chloroquine. 29.5% of PV cases 
were treated with quinine and Doxycycline as they had complications. 70% of 
PF cases responded to quinine and Doxycycline. And only 6 PF cases ( 15%) 
responded to chloroquine. 
 Total of 154 patients treated with chloroqine , 106 (68.8%) responded 
and 48 patients (31.2%) were found to be resistant. 
 In our study quinine was found to be very effective in complicated 
malaria and PF patients. Early initiation of quinine resulted in reducing 
morbidity and mortality. In cerebral malaria quinine was very valuable leading  
to rapid recovery in one or two doses. Regarding side effects of quinine, 
vomiting was the commonest to be noted and other complications like QTc 
prolongation and ambylopia were not found in our study. 
 This study has highlighted that plasmodium falciparum contributes to 
16% of malaria in Chennai. Complications occurred in vivax also. There was 
very good response to quinine and Doxycycline in complicated malaria. 
Mortality was low (1.6%). Early diagnosis of malaria, rapid evaluation for 
organ dysfunction and aggressive management was probably responsible for 
this low mortality. 
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SUMMARY 
¾ 250 patients of malaria were analyzed.210 (84%) had Plasmodium vivax and 
40 (16%) had Plasmodium Falciparum. 
¾ Complications of PF (n – 40) – Jaundice 47.5%, Anemia 27.5%, Renal failure 
25%, Cerebral malaria 15%, ARDS 2.5%,Thrombocytopenia 5% and 
Hypoglycemia 5%. 
¾ Complications of PV (n – 210)  - Jaundice 11.4%, Anemia 13.8%, Renal 
failure 7.6%, Cerebral malaria 12.5%, ARDS, Thrombocytopenia and 
Hypoglycemia  in two cases, CVT in three cases. 
¾ Jaundice occurred in 11.4% of PV and 47.5% of PF cases. Mean Bilirubin 
noted was 5.3mg/dl, predominantly of direct bilirubinemia with mild 
elevations of transaminases in the range of 40 to 80 IU/L. This Shows that 
jaundice in malaria is predominantly of cholestatic in origin. 
¾ Renal failure occurred in 7.6% of PV and 25% of PF cases. Overall renal 
failure occurred in 10.6% of malaria. Mean creatinine and urea noted were 
2.6mg/dl and 99.5mg/dl respectively. 76% of ARF was mild (Serum 
Creatinine 1.5 to 3mg/dl) 
¾ 48.8% of patients had Hb <10g/dl. Only three patients had Hb <5g/dl and 37 
patients (14.8%) had Hb in the range of 5 to 8g/dl. 13.8% of PV and 23% of 
PF had Hb <8g/dl. Mean Hb noted was 8.5g/dl. 
¾ Cerebral malaria occurred in 13.2% of cases. Predominant presentations were 
altered behaviour, loss of conciousness (51%) and Generalized convulsions 
(48%). 12.8% of PV and 15% of PF patients had cerebral malaria. 
¾ Other complications are less common. They were ARDS 1.2%, 
Thrombocytopenia 1.6%, Hypoglycemia 1.6% and CVT 1.2%. 
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¾ 42.4% were treated with chloroquine and 36% were treated with quinine in 
combination with Doxycycline. 19.2% were found to be chloroquine non 
responsive and later switched over to quinine with good response. 
¾ Artemisinin group of drugs used in six patients in whom quinine was 
contraindicated as they had ischemic heart disease. 
¾ Mortality – Four patients (1.6%) died, Three (1.4%) in Vivax and One (2.5%) 
in Falciparum. MODS was the cause of death in three out of four patients and 
one died of cerebral malaria  
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CONCLUSIONS 
 
¾ Plasmodium vivax occurred in 84% and Plasmodium falciparum in 
16%. 
¾ Jaundice 47.5% and Renal failure (25%) were the important 
complications in Plasmodium Falciparum where as cerebral malaria 
occurred only in 15%. 
¾ All severe complications like jaundice(11.4%), renal failure(7.6%), 
cerebral malaria(12%), severe anemia(13.8%) and ARDS(1.2%) were 
noted in Plasmodium vivax though less common compared to 
Plasmodium falciparum. 
¾ Early detection of organ dysfunction utilizing Serum Creatinine 
>1.5mg/dl, total bilirubin >1.5mg/dl and Hb <8g/dl is valuable in 
diagnosing complicated malaria early and starting aggressive 
management (Quinine and Doxycycline ), thereby preventing further 
morbidity and mortality. 
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    PROFORMA 
 
Name :     Age:    Sex: 
IP No. 
PV/PF 
 
Clinical Features: 
• Fever – Duration/paroxysm 
• Chills 
• Headache 
• Vomiting 
• Myalgia 
• Hepatosplenomegaly 
• Icterus 
• Altered sensorium 
• Convulsions 
• Loss of consciousness 
• Diarrhea  
 
Laboratory profile 
• Hemogram 
• Renal function tests 
• Liver function tests 
• Plasma glucose. 
• ECG 
• Chest X Ray 
• USG – Abd. 
 
Treatment 
• Chloquine 
• Quinine 
• Chloroquine  changed to quinine 
• Other drugs. 
 
 
 
 
